PCSK9 Drug Reduces Heart Disease Risk
An expensive new drug, evolocumab (Repatha), developed by Amgen, significantly drops cholesterol levels and reduced the risk of major cardiovascular events, researchers reported in a study published last week (March 17) in the New England Journal of Medicine.
Evolocumab is a monoclonal antibody that attempts to mimic a mutation in the PCSK9 gene, which can lower the risk of developing heart disease by up to 88 percent. A 2014 placebo-controlled study of 901 patients revealed the evolocumab could reduce low-density lipoprotein (LDL) cholesterol levels by around 60 percent. Clinical trials of alirocumab (Praleunt), a competitor drug developed by Sanofi and Regeneron, have revealed similar effects.
The latest study of evolocumab—a randomized, double-blind, placebo-controlled trial involving more than 27,000 patients—revealed that after two years of treatment, only 9.8 percent of patients experienced a major cardiovascular event, such as a stroke or heart attack, compared to 11.3 percent in the placebo group.
William Hiatt, a physician at the University of Colorado in Denver who was not involved in the study, told Science that that results showed that “a physician would need to treat about 150 patients with Repatha in a year to prevent one of these bad events.” Hiatt added that “the benefit here is meaningful and substantial . . . although not overwhelming.” …>> Read more
Source: The Scientist